Vaginal Yeast Infection treatment: SCYNEXIS announces positive top-line results from its second pivotal Phase 3 Study of Oral Ibrexafungerp
by Press Release from Outbreak News Today on (#52JAD)
SCYNEXIS, Inc. announced this week positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment for women with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. With these results, ibrexafungerp has now achieved superiority over placebo with a high degree ["]
The post Vaginal Yeast Infection treatment: SCYNEXIS announces positive top-line results from its second pivotal Phase 3 Study of Oral Ibrexafungerp appeared first on Outbreak News Today.